Overview

PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This study aims to explore new PERS prediction model can improve the pathological complete response rate of neoadjuvant chemotherapy of breast cancer and disease-free survival.
Phase:
Phase 3
Details
Lead Sponsor:
Shi Yanxia
Treatments:
Capecitabine
Cisplatin
Docetaxel
Epirubicin
Gemcitabine
Trastuzumab
Vinorelbine